Innogen Completes A New Round of Financing, Led by KIP

(VCBeat) Apr. 22, 2021 -- Shanghai-based Innogen Pharmaceutical Technology Co., Ltd. ("Innogen") recently completed a new round of financing, led by Korea Investment Partners and Cowin Capital, with participation from BioTrack Capital, Aplus Capital, and Pavilion Capital. Proceeds from the financing will be used for the Phase III clinical trials of suparuptide, the promotion of multiple products and the construction of GMP-compliant production lines.

Innogen is a high-tech, innovation-driven international pharmaceutical manufacturing and R&D company. The company adheres to the philosophy of dedication to innovation and human health. Its core management team consists of well-known Chinese and international experts in diabetes and endocrinology, and senior professionals in new drug R&D and enterprise management. 

Innogen has number of patents with intellectual property rights for diabetic metabolic diseases at internationally advanced level of translational medicine. 

Under the leadership of Professor Wang Qinghua, Innogen has developed a long-acting  biological drug for diabetes, the suparuptide injection, which can not only promote the secretion of insulin, but also may promote the regeneration of β-cell, and is expected to be a cure for diabetes.

As an affiliate of Korea Investment Holdings, which is one of the top financial conglomerates in Korea, KIP is a leading venture capital and private equity with ample investment experience. For more than 30 years since 1986, KIP has shown steady and unprecedented investment performances in various industries.

From early-stage ventures to growth-stage companies, KIP's investments deliver a unified goal to create more values by forging strong relationships integral to building business across different industries.

Cowin Capital Group was established in 2000 and has invested in more than 300 companies, of which 60 more became public companies, and 150 more successfully exit. It focuses on investing in pioneering enterprises with steady development on long-term basis.